tell you why nobody asks you a question Ivy ...
you claim so much but deliver so little
an example post .... one that is ruled by stupidity
Ivyspivey - 31 Jan 2025 - 11:56:49 - 16927 of 17121 Scancell - Pot of Gold or POS? - SCLP
You know perfectly well that we were both referring to an Infectious disease Vax platform not oncology.
Please let me know where the status of SCLP ID Vax Platform is now.? |
i see the Prat is at it again sci
scib1 (which is not even scancell's invention)
so who's invention is it ? |
what is also interesting
why has Nobody asked Ivy for His thoughts !!
how sad is that !! |
as Chester has now reminded you Ivy .....
you really need to keep up with whats already posted ! |
then you have SC102 ... who is convinced that Lindy has been around longer than Global warming and Queen Victoria !! |
Nigel,True and a good price for both parties would be £1.50. Glad you came round in the end :) |
2tyke,Investment funds and pension funds have to have a way of "valuing" companies they invest in. They do this using fairly industry standard methods based on yield. In order to apply that to Scancell who do not have any revenue or yield you have to try and work out what that might be if ever they got to a position of earning revenue what that yield might be. Not perfect, but you have to start somewhere don't you? |
You've not grasped that big pharma don't just chuck money about for fun either. They'll evaluate and pay a good price for them. |
Which one has failed?
Well, keytruda is successful beyond any doubt. SCIB1 has been in clinical development for 355 years more or less, to the point where patents have expired. So yeah, scib1 is infinitely closer to failure than Keytruda, why don't you stop asking that stupid question already? |
and surely if you are smart Ivy why can't you answer it yourself
rather than using Ask the Audience
creating an "average answer"
because nobody can be definitive |
Ivy .... problem for you, nobody is interested in you
Bermuda even left you hanging yourself |
again No business Acumen
ATB
you can't think for others Ruck
if you have no business acumen |
Yep very happy for Marcus to answer specifically why does he think SCLP have gone for Cohort 4.Only interested in that response not the other stuff. |
"and you want to sell your share at ?1.5"I'd LOVE to sell my shares for £1.50 yes, so would 99% of investors. |
"Ruck what is the royalty per year at 17.5% of $9 billion"$1.575 billion. |
and you want to sell your share at £1.5 |
Nigel,You don't seem to have grasped the fact that just because some investors are prepared to sell for a few pennies that this has no bearing on the future or potential value. A PI may think 9p is a good buy if they can sell for 15p in a few weeks. A big pharma may think £1 is a good price if it opens up a $3.5B market. Chalk and cheese. |
Rucks maths ....
Ruck what is the royalty per year at 17.5% of $9 billion |
Many of us think that x10 or more is very achievable.
Hang on. That's a very different point. Even I believe that is achievable!
My point was simply that a RNS landing at some point with a knock out bid at > 10x the current price is NOT going to happen. |
"read the posts Mr Data Scientist"You mean you can't answer? It's a simple question, either you know the answer or you don't. |
marcus tell me ... and be honest
did you understand the posts i made today ?
did you see any points that may need Fine tuning or debating |
It is always the other persons fault that they cant understand your responses.
OK I must be too thick to see so can anyone else explain from Nana posts what the answer is.
No matter I have asked on LSE where other contributors may give a more informed opinion. |
Many of us think that x10 or more is very achievable.
I don`t think some people can get their heads around what the platforms will be worth if the data is decent.
Off the shelf, huge profit margin for big pharma, safe, no big side-effects.
Moditope can cover many different solid tumours.
If Modi-1 in RCC does even better than Head & Neck (an early 43% response rate versus 13% best response with current treatments) we should rocket.
That may also encourage Big Pharma to try Ovarian etc with CPIs which are not approved for Ovarian yet.
Modi-2 could be an even bigger prospect but prove Modi-1 first then watch the fun and games when the big players scramble to license or buy out Scancell.
Inan, myself and others are loaded up. Let`s see who is laughing at the end game! |
thank you for your comments Ivy ...
respectfully you are to stupid to understand them anyway ... |
Nana I have never tried to disrespect iSCIB as evident to me that is the direction which SCLP want to go.
No worries if you can’t answer my question but would be much easier if you just replied I dont know rather than endless posts which just confuses everyone.
Then you claim they don’t understand whereas the reality is you are such a poor communicator people just give up.
Anyway rugby to prepare for |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
